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Much progress has been made in the treat-
ment of acute burn injury with overall improved 
patient survival. A key component of this success 
derives from early excision and skin grafting of the 
burnt areas, which helps restore altered physiol-
ogy including fluid dysregulation, metabolic dis-
turbances, and systemic inflammatory response 
syndrome.1–8 While autografts are preferred for 
definitive closure of these wounds, the lack of 
sufficient donor skin may necessitate the use of 
cadaveric allografts, which remains the treatment 
of choice for temporary wound coverage.9 Appli-
cation may be limited by cost and availability con-
siderations however.
Alternative skin options include porcine xeno-
grafts consisting of dermis (EZ Derm, Brennan 
Medical, St. Paul, MN) or both epidermis and 
dermis (Mediskin, Brennan Medical, St. Paul, 
MN)9 that have been used, after chemical process-
ing, in burn care patients clinically10 due to shared 
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Cadaveric skin allograft is the current standard of treatment for temporary coverage of 
large burn wounds. Porcine xenografts are viable alternatives but undergo α-1,3-galactose 
(Gal)–mediated hyperacute rejection and are lost by post-operative day (POD) 3 because of 
naturally occurring antibodies to Gal in primate recipients. Using baboons, we previously 
demonstrated that xenografts from GalT-KO swine (lacking Gal) provided wound coverage 
comparable with allografts with systemic immunosuppression. In this study, we investigate 
topical immunosuppression as an alternative to prolong xenograft survival. Full-thickness 
wounds in baboons were created and covered with xenogeneic and allogeneic split-thickness 
skin grafts (STSGs). Animals were treated with slow-release (TyroSphere-encapsulated) topical 
formulations (cyclosporine-A [CSA] or Tacrolimus) applied 1) directly to the STSGs only, or 
2) additionally to the wound bed before STSG and 1). Topical CSA did not improve either 
xenograft or allograft survival (median: treated grafts = 12.5 days, control = 14 days; P = 0.27) 
with similar results when topical Tacrolimus was used. Pretreatment of wound beds resulted 
in a significant reduction of xenograft survival compared with controls (10 vs 14 days; P = 
0.0002), with comparable results observed in allografts. This observation was associated with 
marked reduction of inflammation on histology with Tacrolimus and not CSA. Prolongation of 
allograft and xenograft survival after application to full-thickness wound beds was not achieved 
with the current formulation of topical immunosuppressants. Modulation of inflammation 
within the wound bed was effective with Tacrolimus pretreatment before STSG application 
and may serve as a treatment strategy in related fields. (J Burn Care Res 2018;39:363–373)
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characteristics with human skin such as structural 
similarity of the rete ridges, papillary dermis, and 
epidermal thickness.11–15 However, typically by 72 
hours after application, these xenografts often fail 
due to nonvascularization resulting from hyperacute 
rejection mediated by naturally occurring antibodies 
to α-1,3-galactose (Gal), a cell-surface antigen pres-
ent on all porcine cells,15,16 that are found ubiqui-
tously in primates.
Our laboratory has a genetically engineered herd 
of swine that lack the Gal moiety (GalT-KO).17 
Organs and tissues from these GalT-KO pigs can 
thus be utilized, without the requirement for 
complement inhibition or antibody absorption, 
in xenotransplantation models of kidney, heart, 
liver, and skin12,18–20 without the development of 
hyperacute and acute humoral xenograft rejection. 
We have also recently demonstrated that GalT-
KO skin grafts provided skin coverage comparable 
with allografts (median survival of xenografts = 14 
days, allografts = 13 days) in baboon recipients.21 
Prolongation of temporary burn wound coverage 
with alternative skin options would therefore be of 
considerable clinical benefit in allowing healing of 
autologous donor sites in the interim before rehar-
vest for definitive wound closure.
Besides mitigation of immune responses through 
GalT-KO, systemic immunosuppression after burn 
injury has been demonstrated to have an associa-
tion with prolonged allograft skin survival.22 Sys-
temic immunosuppressive therapy may conceivably 
prolong both the survival of allogeneic and xeno-
geneic skin grafts but would, however, be unde-
sirable in the context of severe burns in an already 
immunocompromised and critical patient. Topical 
delivery of immunosuppression would therefore 
represent an attractive alternative without the asso-
ciated risks of systemic absorption. In the clinic, 
topical creams of Tacrolimus and steroids are cur-
rently available (e.g., Protopic, clobetasol) but 
frequent reapplication is required. Moreover, the 
highly lipophilic nature of these topical prepara-
tions and their poor absorption across the stra-
tum corneum barrier23 may result in variable tissue 
dosages.24
To overcome the aforementioned limitations with 
topical immunosuppression, various skin penetra-
tion enhancers such as Azone, dimethyl sulfoxide, 
menthol, and both lipophilic and hydrophilic vehi-
cles have been used to improve drug absorption,25 
but these lipid-based colloidal systems have limited 
drug loading and low stability, thereby reducing their 
clinical use.26 Kohn et al have developed biodegrad-
able nanoparticles made of tyrosine-derived tri-block 
copolymers (referred to herein as TyroSpheres). 
TyroSpheres are amphiphilic, self-assemble to form 
a hydrophobic core to house lipophilic molecules 
(e.g., cyclosporine-A [CSA],27 Paclitaxel28) and have 
an external hydrophilic shell that enhances aqueous 
stability.29 They have also been shown to provide con-
trolled drug release,27,28 improve skin penetration of 
hydrophobic agents,30 and can be formulated into a 
gel dressing without easy “run-off.”27 Thus, the use 
of TyroSpheres can conceivably provide a convenient 
topical application schedule while maintaining contin-
uous local release of the pharmaceutical26 and avoid 
systemic drug absorption and related complications.
By building on our previous work in which GalT-
KO xenogeneic and allogeneic skin graft survival 
could not be prolonged despite additional systemic 
immunosuppression,21 the objectives of this study 
are: 1) to characterize the release of immunosup-
pressants from TyroSpheres in vitro, 2) evaluate the 
safety of TyroSpheres in a nonhuman primate (NHP) 
model, and 3) determine if topical immunosuppres-
sant-loaded TyroSpheres alone could prolong the 
survival of GalT-KO xenogeneic and allogeneic skin 
grafts in an NHP model.
METHODS
Preparation of TyroSpheres Loaded With 
CSA or FK506
Polymeric micelles were prepared via a self-
assembly technique. Preparation of the empty 
(vehicle only) and CSA-loaded TyroSpheres has 
been reported previously.27 For FK506-loaded 
Tyrospheres, polymer (60 mg/0.3 ml) and drug 
(60 mg/ml, equivalent to 30% wt/wt initial load-
ing) were each dissolved in dimethyl formamide, 
mixed in equal amounts (0.3 ml each) and added 
drop-wise to phosphate-buffered saline (PBS; 
14.4 ml) with constant stirring. The resulting 
suspension was passed through 0.22 μm polyvi-
nylidene fluoride (PVDF) filters (Millipore) and 
ultra-centrifuged for 3 hours at 65,000 RPM and 
18ºC. The supernatant was then aspirated, poly-
meric micelles rinsed twice with PBS, resuspended 
in PBS, ultra-centrifuged again before resuspen-
sion in PBS overnight at 25 ± 2ºC. FK506-loaded 
TyroSpheres with 10, 20, 40, 50, and 60 wt% the-
oretical drug loading were similarly prepared and 
characterized for loading efficiencies and actual 
(measured) loading content.
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Determination of Drug Concentration Using 
HPLC
A Waters 2695 High-Performance Liquid Chro-
matography (HPLC) and Empower Pro software 
(Waters, Milford, CT) was used for validation of our 
FK506 method. Optimized chromatographic condi-
tions include column—Waters-C18, 2.1 × 50 mm, 5 
μm particle size; column temperature—50ºC; injec-
tion volume—10 μL; detection wavelength—213 nm; 
mobile phase: A = HPLC water: B = acetonitrile (ACN; 
isocratic A:B [42.5:57.5]); flow rate—0.5 mL/min; 
run time—8 minutes; sample diluent—ACN.
Standards were prepared by making 1 mg/ml 
solution of FK506 in ACN before diluting to 500 
µg/ml. Remaining standards were prepared by 
serial dilution to reach 7.8 µg/ml. A 100 µl aliquot 
of FK506-Tyrospheres was then lyophilized and 
extracted into 2 ml of ACN and filtered with 0.44 
µm filters into HPLC vials. Samples were analyzed 
by the above parameters to determine the concentra-
tion of FK506 in TyroSpheres. HPLC quantification 
of CSA has been described.27
Loading Content and Loading Efficiency
Loading content and efficiency were determined by 
adding aliquots of drug-loaded (varying theoretical 
loading, 10–60 wt%, as described above) and empty 
TyroSpheres to PBS in preweighed vials. Samples 
were frozen on dry ice, lyophilized for ≥ 24 hours, 
and reweighed to determine the mass of salts, and 
empty and drug-loaded TyroSpheres. Two milliliters 
of ACN was added to loaded TyroSphere samples 
followed by 1 hour of vigorous vortexing to deter-
mine drug mass. Drug quantification was determined 
by HPLC and a standard curve. Equations used were
Loading Content
TyroSpheres
Tyro
(%)
mass of FK506 in the 
mass of
=
Spheres
X100  (1)
Loading Efficiency(%)
mass of  
mass of
=
FK in the TyroSpheres
FK
506
506 in the feed
X100  (2)
Release of FK506 From TyroSpheres
FK506 release was examined using 0.5 mL dialysis 
cassettes with a 10,000 molecular weight cut-off 
(MCWO) cellulose dialysis membrane (Slide-A-
Lyzer, Fischer, Pittsburgh, PA). FK506-loaded 
TyroSpheres were diluted with PBS to a drug con-
centration of 400 µg/ml and added to the cassettes. 
Once loaded, cassettes were submerged in 200 mL 
of PBS and stored in a shaking (60 rpm) water bath 
at 37°C. Cassette content was then collected at pre-
determined time points for up to 168 hrs and added 
to the washed (rinsed 3 times with fresh PBS) com-
partment of these cassettes. FK506 concentration 
was determined from the donor compartment of 
cassettes via HPLC subsequent to lyophilization and 
extraction with ACN. The released FK506 within the 
receptor compartment was below detection limits by 
mass balance due to its large volume. CSA release 
from TyroSpheres has been described previously.27
Preparation of 30 wt% FK506-
TyroSpheres-1% (wt/vol) HPMC Gel 
Formulation
Hydroxypropyl methylcellulose (HPMC, 150 mg) 
was suspended in 10 ml of 1× PBS and stirred at 
400 rpm (to avoid bubble formation) for 48 hours 
at 25°C. Five milliliters of FK506-TyroSpheres (30 
wt%) were then syringe filtered (0.22 μm, Millipore) 
and mixed with 1.5% (wt/vol) HPMC gel (10 ml) to 
create a suspension of 30 wt% FK506-TyroSpheres in 
1% (wt/vol) HPMC gel (referred herein as FK506-
TyroSpheres-gel), and stirred for 18 hours at room 
temperature. The suspension was then stored at 4°C 
until use.27 Vehicle-only controls were similarly pre-
pared by replacing FK506-loaded Tyrospheres with 
empty TyroSpheres before mixing with 1.5% (wt/
vol) HPMC gel as described above.
Animals
This study was approved by the Massachusetts Gen-
eral Hospital Institutional Animal Care and Use 
Committee and the U.S. Army Medical Research 
and Materiel Command Animal Use and Review 
Office and performed in accordance with The Guide 
for the Care and Use of Laboratory Animals.31 Thir-
teen baboons (Papio hamadryas) were obtained 
from Mannheimer Foundation, Inc, Homestead, 
FL. All baboons were aged 2 to 5 years, weighed 7 to 
12 kilograms each, and underwent routine pathogen 
screening and quarantine before commencement of 
experimental studies.
Genetically-engineered GalT-KO miniature swine 
were produced in our swine facility.18 The GalT-KO 
swine herd is monitored using a computerized system 
to ensure availability and quality control and housed in 
a purpose-built facility, which is fully integrated as part 
of the animal facilities in the laboratory with input and 
veterinary oversight from the Center for Comparative 
Medicine of the Massachusetts General Hospital.
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Skin Graft Harvest
GalT-KO donor swine were anesthetized with I.M. 
Telazol 2 mg/kg, intubated, and had anesthesia main-
tained with 2% isoflurane and oxygen. Presurgery, the 
area of donor skin was disinfected with 2% chlorhexi-
dine acetate (NolvasanR Surgical Scrub, Fort Dodge 
Animal Health, Fort Dodge, IA), 70% isopropyl 
rubbing alcohol (NolvasanR Surgical Scrub, Owens 
& Minor, Mechanicsville, VA), and 10% povidone-
iodine (Betadine Solution, Purdue Products, L.P., 
Stamford, CT) before sterile draping. An air-driven 
Zimmer dermatome (Medfix Solution, Inc., Tucson, 
AZ) with a depth of 0.022 inches was used to harvest 
split-thickness skin grafts (STSGs) from the dorsum 
of the animal. Saline and epinephrine soaked gauze 
was applied to skin donor sites for hemostasis before 
dressing with Telfa™ (Covidien, Dublin, Ireland) and 
Tegaderm™ (3M, St. Paul, MN).
Baboon donors were sedated with I.M. atropine 
0.1 mg/kg and I.M. ketamine 20 mg/kg, shaved, 
and transferred to the operating room for endotra-
cheal intubation and general anesthesia with 2% iso-
flurane and oxygen similar to the above. Skin donor 
sites on the baboon’s back was prepped as described 
above for GalT-KO swine.
Wound Preparation and Skin Graft 
Placement
Baboon recipients were premedicated, shaved, anes-
thetized, and prepped as described above. Sharp 
excision of full-thickness skin down to muscle was 
performed to create defects measuring 4 × 5 cm. 
STSGs were fenestrated before application onto 
these defects. TyroSpheres-gel dressings were then 
applied as described below before pressure dress-
ings were created with sterile dry gauze and secured 
with VetrapTM (3M, St. Paul, MN) bandaging tape 
to reinforce the underlying TelfaTM and TegadermTM 
wound dressings placed over the STSG.
Experimental Design
Thirteen baboons were used in 4 experiments. The 
first 3 experiments were designed for toxicity and 
dose titration studies (Table 1) while the final experi-
ment investigated the clinical efficacy of CSA- and 
FK506-TyroSpheres-gel dressings (Table 2).
In experiment 1, each animal received 3 autolo-
gous STSGs: 1) control (BacitracinTM only, no Tyro-
Spheres application), 2) TyroSpheres-gel (vehicle 
only) dressing applied immediately postoperatively, 
and on alternate days thereafter, and 3) TyroSpheres-
gel (vehicle only) dressing applied on alternate days 
from the second postoperative day. Previous experi-
ence with other topical immunosuppressants suggests 
that treatment in the immediate postoperative phase 
may impair vascularization of the STSG (data not 
published), hence the inclusion of a delayed treat-
ment option. TyroSpheres-gel dressings were applied 
directly to the STSGs, with each application consist-
ing of an empiric dose, sufficient to lightly coat the 
STSG with minimal excess as topical agents are most 
frequently applied in this manner in the clinic.
In experiment 2, animals that were previously 
sensitized to xenogeneic and allogeneic STSGs 
were chosen. Once the STSG was secured, a 2.0 ml 
dose of CSA-TyroSpheres-gel dressing (containing 
~2.5 mg/ml CSA) was applied, in preference to the 
previously used empiric-dosing scheme in order to 
standardize the dose of CSA being administered and 
to facilitate interpretation of systemic uptake data, 
followed by standard dressings as before. STSGs 
were assessed, and CSA-TyroSpheres-gel dressings 
(2.0 ml) reapplied on alternate days. Systemic uptake 
Table 1. Toxicity and dose titration studies
Experiment N
Skin Grafts  
Per Animal Treatment Treatment Frequency
Study  
End Point
1 (empty vehicle) 2 3 autologous STSGs • Control (BacitracinTM)
• TyroSpheres-gel (from POD 0)
• TyroSpheres-gel (from POD 2)
Every other day up to 
POD 8
POD 14
2 (toxicity and 
systemic uptake)
2 1 autologous STSG •  2.0 mL CSA-TyroSpheres-gel dressing 
(from POD 0)
Every other day POD 14
3 (dose response) 1 4 autologous STSGs •  CSA-TyroSpheres-gel dressing (from 
POD 0)
• 0.2 ml
• 0.5 ml
• 1.0 ml
• Control (BacitracinTM)
Every other day POD 14
CSA, cyclosporine-A; POD, postoperative day; STSG, split-thickness skin graft.
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of CSA was assessed by submission of peripheral 
blood samples for standardized assay.
In experiment 3, three autologous STSGs were each 
treated with a different volume (0.2, 0.5, or 1.0 ml) of 
CSA-TyroSpheres-gel dressing on alternate days. The 
fourth STSG served as an internal control (with Baci-
tracinTM) and was not treated with CSA-TyroSpheres-
gel dressings. Peripheral blood was drawn on alternate 
days for monitoring of CSA uptake.
In experiment 4, eight baboons received a series 
of STSGs as described previously.21,32 Briefly, each 
baboon received 4 STSGs on separate full-thickness 
wounds on the dorsum with GalT-KO xenografts 
placed first. Following rejection, the wound beds 
were debrided and allogeneic STSGs were placed. 
Recipient animals in Groups 1A and 2A were then 
treated with CSA- and FK506-TyroSpheres-gel 
dressings every other day respectively until rejec-
tion. In groups 1B and 2B, CSA- and FK506-Tyro-
Spheres-gel dressings were applied at the time of 
surgery (before anchoring down of STSG) to assess 
whether immunosuppression bioavailability might 
be a confounding factor, followed by every other day 
application as described in groups 1A and 2A.
Clinical and Histological Assessment
Recipients underwent clinical evaluation every other 
day during which TyroSpheres-gel application was 
repeated and fresh dressings applied, up to post-
operative day (POD) 14. Skin grafts were assessed 
for viability and integrity and determined to be 
rejected when less than 10% of viable graft tissue 
covered the wound.33 Median graft survivals were 
compared using a log-rank test in GraphPad Prism, 
version 5.04 for Windows, GraphPad Software (San 
Diego, CA). Six millimeter punch biopsies were 
taken from viable areas of the grafts at 4-day inter-
vals postoperatively and H&E stained slides were 
evaluated for features of rejection by a pathologist 
blinded to specimen identity.
RESULTS
Drug Loading Content and Loading 
Efficiency
Figure 1 shows the drug loading content and load-
ing efficiency of FK506 into TyroSpheres with the 
theoretical loading content ranging from 10% to 
60% (wt/wt) following 2 ultracentrifugation steps, 
which are required to ensure proper purification of 
the TyroSpheres for subsequent evaluation in vivo. It 
was determined that the loading efficiency of FK506 
into TyroSpheres was similar (40–50 wt%) regard-
less of theoretical loading content. The ~50% loss of 
drug occurs during the washing and filtration steps 
of the process. It is important to note that despite 
this loss of drug, the actual loading content nearly 
equals the theoretical loading content, suggesting 
that the actual (measured) loading content is very 
close to the theoretical loading content. Previous 
Table 2. Design of experiment 4 to evaluate clinical efficacy of CSA- and FK506-TyroSpheres-gel dressings
Group N Primary Grafts Secondary Grafts Treatment
1A 2 GalT-KO xenogeneic STSG Allogeneic STSG CSA-TyroSpheres-gel dressings on alternate 
days
1B 2 GalT-KO xenogeneic STSG Allogeneic STSG CSA-TyroSpheres-gel dressings to wound 
bed before STSG and on alternate days 
thereafter
2A 2 GalT-KO xenogeneic STSG Allogeneic STSG FK506-TyroSpheres-gel dressings on 
alternate days
2B 2 GalT-KO xenogeneic STSG Allogeneic STSG FK506-TyroSpheres-gel dressings to wound 
bed before STSG and on alternate days 
thereafter
CSA, cyclosporine-A; FK506, Tacrolimus; GalT-KO, α-1,3-galactose (Gal) knock-out; POD, postoperative day; STSG, split-thickness skin graft.
Figure 1. Loading content and loading efficiency of 
FK506-loaded TyroSpheres with theoretical loading con-
centrations ranging from 10 to 60 wt%.
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studies have shown that a theoretical loading content 
of 30 wt% was the maximum amount of CSA that 
could be loaded into TyroSpheres with a loading 
efficiency of nearly 50%.27 To compare the safety and 
efficacy of similar doses of drug, subsequent studies 
reported herein use 30 wt% CSA- or FK506-loaded 
TyroSpheres.
In Vitro Release of FK506 From TyroSpheres
Figure 2 shows the release profile of 30 wt% FK506 
from TyroSpheres in PBS at 37°C under sink con-
ditions. An initial burst was observed where 29% 
of the payload was released from the TyroSpheres 
within 8 hours of incubation, followed by sig-
nificantly slower release kinetics throughout the 
remainder of the study (38% at 24 hours, 42% at 3 
days, and 50% at 7 days). As previously reported, 30 
wt% CSA-loaded TyroSpheres provided an initial 
burst release of 23% of the payload within 24 hours, 
followed by a sustained release of the remaining 
drug over the next 7 days (52% at 3 days and 75% at 
7 days).27 The release of FK506 from TyroSpheres 
was significantly slower than CSA, probably due to 
the more hydrophobic nature of FK506 compared 
with CSA.
Toxicity and Dose Titration Studies
In experiment 1, application of TyroSpheres-gel 
(vehicle only) dressing on alternate days had no 
detectible negative effect on graft healing. No signif-
icant difference in outcome was detectable between 
grafts treated from POD 0 and those treated from 
POD 2 (Figure 3). These results suggest that the 
vehicle itself does not have an adverse effect on the 
vascularization of autologous STSGs. This remained 
true at all time points up to POD 8 and following 
cessation of treatment to the conclusion of follow-
up at POD 14. Importantly, it was also observed 
that the skin surrounding the STSG also remained 
healthy. This experiment demonstrated that the 
topical application of TyroSpheres-gel dressing in an 
NHP model was nontoxic.
In experiment 2, STSGs treated with 2.0 mL 
of CSA-TyroSpheres-gel dressings demonstrated 
impaired healing and maceration by POD 4, progress-
ing to sloughing and graft loss by POD 8. At PODs 2 
and 4, the STSG had taken 100% to the new recipient 
site. The degree of bruising observed was within nor-
mal limits for STSGs and consistent with untreated 
control STSGs (data not shown) and indicates that 
the graft microvasculature, which is subject to trauma 
Figure 2. Release profile of FK506 from dialysis cassettes in 1× PBS up to 7 days.
Figure 3. Autografts were treated with empty TyroSpheres-gel to determine if skin graft healing would be affected by the 
vehicle. These photos are taken on POD 8. An untreated autograft was placed as a control (A). No detrimental healing ef-
fects were observed when the empty TyroSphere-gel was applied to an autograft every other day starting on POD 0 (B) or 
on POD 2 (C).
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during the harvest procedure, had established con-
nection with the vasculature of the recipient wound 
bed. However, by POD 6, significant thinning and 
paling of the STSGs was observed in addition to 
maceration of the STSG (Figure 4) and progressed 
to complete loss by POD 8. This phenomenon was 
not observed in groups treated with TyroSpheres-gel 
(vehicle only, experiment 1) dressings. CSA levels in 
the blood were negligible throughout the duration of 
the study. All values were below the sensitivity limit of 
the commercial assay used (Table 3).
In experiment 3, the 1.0 mL CSA-TyroSpheres-
gel dressing–treated STSG showed signs of macer-
ation by POD 6 (Figure 5) and became ulcerated 
by POD 8. Thereafter, 50% of the STSG was lost, 
while the remainder gradually healed. No deleterious 
effects were observed in STSGs treated with 0.2 mL 
and 0.5 mL CSA-TyroSpheres-gel dressings, and 
no significant difference in appearance was noted 
between these and the untreated control STSG. 
Consistent with the result observed in experiment 
2, CSA could not be detected in peripheral blood at 
any time point. Results of this experiment suggested 
that a dose of 0.2 mL or 0.5 mL would avoid nega-
tive effects on STSG healing and would be suitable 
for use in experiment 4 to lightly and sufficiently 
coat the STSG with minimal excess.
Clinical Efficacy Study
Following rejection of xenogeneic STSGs, all wound 
beds were debrided and covered with allogeneic 
STSGs. 0.5 ml CSA- and FK506-TyroSpheres-gel 
dressings were utilized.
In groups 1A and 2A, xenogeneic STSGs from 
GalT-KO swine survived a median of 12.5 and 12 
days when treated topically with CSA- and FK506-
TyroSpheres-gel dressings, respectively, compared 
with a median of 14 days when treated with stan-
dard STSG dressing, that is, BacitracinTM ointment 
(P = 0.27; P = 0.16). Allogeneic STSGs survived 
a median of 14 days when treated with CSA- and 
FK506-TyroSpheres-gel dressings compared with 
a median of 13 days when treated with standard 
BacitracinTM dressing (P = 0.80; P = 0.80; Fig-
ure 6). Biopsies of CSA-TyroSpheres-gel dressings–
treated STSGs also revealed ischemia with clinical 
Figure 4. No deleterious effect was observed clinically in autografts treated with 0.4% CSA-TyroSpheres-gel every other day. 
The grafts were observed on POD 0 (A), POD 2 (B), POD 4 (C), and POD 6 (D).
Table 3. No systemic absorption of CSA was observed 
at any time point postoperatively when autografts were 
treated with 0.4% CSA-TyroSpheres-gel every other day
POD Systemic CSA Level (ng/ml)
0 0.0
2 0.0–0.4
4 0.0–1.7
6 0.0–3.5
CSA, cyclosporine-A; POD, postoperative day.
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appearances similar to control BacitracinTM–treated 
STSGs (Figure 6A, B).
In groups 1B and 2B, xenogeneic STSGs had signif-
icantly shorter survival with a median of 10 days each 
when treated topically with CSA- and FK506-Tyro-
Spheres-gel dressings, which was significantly shorter 
compared with BacitracinTM–treated control STSGs 
(median = 14 days; P = 0.0002; P = 0.0002), despite 
pretreatment with CSA- and FK506-TyroSpheres-gel 
dressings into the wound bed. Allogeneic STSGs sur-
vived a median of 11 and 12 days when treated with 
CSA- and FK506-TyroSpheres-gel dressings, com-
pared with a median of 14 and 13 days, respectively, 
when treated with standard BacitracinTM dressing (P 
= 0.0009; P = 0.0011). The STSGs appeared to take 
clinically but rapidly became ischemic and sloughed 
off by POD 8 (Figure 7). Compared with control-
treated grafts however, FK506-TyroSphere-gel dress-
ings led to profoundly reduced inflammation in both 
the graft and wound bed (Figure 7A, B).
DISCUSSION
Burns are extremely common and can have last-
ing physical and psychological effects on patients. 
According to the latest annual report of the Ameri-
can Burn Association, more than 450,000 patients 
received medical treatment for burn injuries, with 
more than 40,000 of these patients hospitalized.34 
While burn care and treatment have dramatically 
improved over the past 20 years, more than 3000 
deaths in 2015 were associated with burn injuries.34 
In addition, from 2003 to 2007, the burn unit at 
Fort Sam Houston (USAISR) had 1497 hospitaliza-
tions, including 656 military patients, of which 540 
were related to the conflict in Iraq.35
Allograft skin is the current accepted standard for 
the treatment of burn wounds when autologous donor 
sites are insufficient or not available while xenograft 
skin is an alternative option. Either way, rapid wound 
closure is necessary to avoid the sequelae of tempera-
ture dysregulation, fluid and electrolyte imbalance, and 
the risks of infection resulting from the loss of the skin 
barrier. Both allogeneic and xenogeneic skin grafts are 
typically rejected in a matter of days to weeks however, 
and further immunosuppression to halt the rejection 
process is deemed an unacceptable risk in burn patients 
who are already at increased risk of infection. Moreover, 
systemic immunosuppression is associated with other 
side effects including hypertension, nephrotoxicity, 
metabolic syndrome, and cancer.36 Herein, we inves-
tigated the safety and efficacy of the topical delivery of 
immunosuppression (CSA, FK506) using biodegrad-
able nanospheres (TyroSpheres) to prolong allogeneic 
and xenogeneic STSG survival while avoiding systemic 
absorption and exposure to immunosuppressants.
The first 3 experiments demonstrated that CSA- 
and FK506-TyroSpheres-gel could be applied in the 
form of a topical dressing (0.2–0.5 ml) to STSGs from 
both allogeneic and xenogeneic sources without the 
risks of systemic exposure and consequent complica-
tions. However, no significant prolongation of STSG 
survival was observed in vivo with topical or topical 
and wound bed application of CSA- or FK506-Tyro-
Spheres-gel dressing. Of note, histology revealed that 
both xenogeneic and allogeneic STSGs placed on 
wound beds pretreated with FK506-TyroSpheres-
gel had markedly reduced numbers of inflammatory 
cells present, whereas CSA-treated wound beds were 
minimally affected. It is unclear whether the dose of 
the current immunosuppressants was not optimal for 
prolonging skin graft survival or if the drugs them-
selves were unable to prolong skin graft survival.
Figure 5. A dose titration of autografts treated with 0.4% CSA-TyroSpheres-gel every other day demonstrated no adverse 
effect on graft healing when using 0.2 ml or 0.5 ml of the TyroSpheres-gel per graft. However, when 1.0 ml of the Tyro-
Spheres-gel was used, the autografts became macerated and sloughed by POD 12. An untreated control was performed for 
comparison.
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Previous, related studies have investigated the 
topical application of both CSA and FK506 after 
allo-STSG in murine37–39 models. Untreated control 
grafts were typically lost within 7 days but prolonged 
survival (up to > 120 days) could be achieved when 
treated with daily topical CSA or FK506. Of note, 
increased allo-STSG survival with topical CSA was 
associated with systemic absorption of CSA (250–
500 ng/ml)39 but not with topical FK506 (< 0.5 ng/
ml).38 Interestingly, the reduction in cellular infiltra-
tion of STSGs was also observed in the study with 
topical CSA (with systemic absorption).39 The resis-
tance of alloreactive leucocytes to topical CSA may 
account for this phenomenon, although it may subse-
quently be overcome by increased dosaging (and pre-
sumably, systemic absorption).40 In contrast, systemic 
absorption of CSA and FK506 was not observed in 
our study even though decreased cellular infiltration 
was observed with FK506-TyroSpheres. Perhaps the 
difference in skin structure between animal models 
and immunosuppressant carrier for topical delivery in 
these studies may account for these discrepancies.
We therefore postulate that the dramatic reduction 
in inflammatory cells observed in our study impaired 
angiogenesis and vascularization of the STSGs, 
ultimately leading to non-take due to ischemia, 
Figure 6.  A. Kaplan-Meier survival analysis for xenogeneic and allogeneic skin grafts treated with standard BacitracinTM or 
CSA/FK506-TyroSpheres-gel. Representative histology at 400× magnification showing hematoxylin and eosin–stained slide 
from a biopsy taken on POD 6 of an allograft treated with CSA-TyroSpheres-gel (B). Diffuse dermal rejection (*) with ische-
mic changes in the epidermis is seen in this graft. (C) Shows a 400× magnification hematoxylin and eosin–stained slide from 
a biopsy taken on POD 4 of an allograft treated with the standard wound care agent, BacitracinTM. This graft demonstrated 
early epidermal changes (†) consistent with ischemia and early rejection.
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suggesting that early graft loss was not mediated by 
adaptive immunity. To conclude, topical delivery of 
slow-release immunosuppressants through Tyro-
Spheres alone does not significantly prolong either 
allograft or xenograft survival on full-thickness 
wound beds; however, preapplication to the wound 
bed was effective at reducing subsequent inflamma-
tion both in the wound bed itself and the STSG.
Future work will focus on the delivery of dif-
ferent immunosuppressive agent(s) with different 
mechanism(s) of action in vivo. Potential drugs 
include those that inhibit T cell targets, which are 
considered important in the rejection of skin.41 We 
will also study the effect of these topical, slow release 
immunosuppressant-loaded products on the immu-
nological reaction to and survival of allogenically 
transplanted primarily vascularized skin flaps.
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